Jazz Pharmaceuticals owes refunds to 340B providers, according to a notice posted on the Health Resources and Services Administration’s Office [...] …
Articles by : Rich Daly, Editor in Chief
The 2024 outlook for not-for-profit hospital and health systems improved from negative to stable, in part, due to the planned [...] …
The average hospital in the 340B program charges commercial insurers more than non-340B hospitals, according to a new report, which [...] …
GlaxoSmithKline owes refunds to 340B providers, according to a notice posted on the Health Resources and Services Administration’s Office of [...] …
A recent ruling by a federal district judge in South Carolina potentially could expand 340B-eligible prescriptions, say some provider advisers. [...] …
Hospital advocates praised the recent Medicare final rule implementing a $9 billion lump sum payment to 340B hospitals but worried [...] …
Medicare Part B will continue to pay hospitals for 340B drugs at the rate of average sales price (ASP) plus [...] …
Medicare issued a final rule today to implement a $9 billion lump sum payment to 340B hospitals and to cut [...] …
Forty-four health systems and hospitals sued federal healthcare agencies over their recent decision to end a 340B COVID-related registration flexibility [...] …
Lobbying on 340B issues in 2023 remains on track for a record-breaking year, according to recently released congressional lobbying reports. [...] …